{
    "id": "71749e1b-ffba-47c7-959a-edac40f135fb",
    "indications": "severe primary igf-1 deficiency ( primary igfd ) increlex indicated treatment growth failure pediatric patients 2 years age older : severe primary igf-1 deficiency growth hormone ( gh ) gene deletion developed neutralizing antibodies gh . severe primary igf-1 deficiency ( igfd ) defined : height standard deviation score ≤ –3.0 basal igf-1 standard deviation score ≤ –3.0 normal elevated growth hormone ( gh ) .",
    "contraindications": "increlex administered subcutaneously . ( 2.2 ) injection sites rotated avoid lipohypertrophy . ( 2.2 ) recommended starting : 0.04 mg/kg 0.08 mg/kg twice daily . well-tolerated least one week , dose may increased 0.04 mg/kg per dose , maximum dose 0.12 mg/kg given twice daily . ( 2.1 )",
    "adverseReactions": "known hypersensitivity increlex used patients allergic mecasermin ( rhigf-1 ) inactive ingredients increlex , experienced severe hypersensitivity increlex [ ( 5.2 ) ( 6.3 ) ] . closed epiphyses increlex used growth promotion patients closed epiphyses . malignant neoplasia increlex contraindicated pediatric patients malignant neoplasia history malignancy [ ( 5.7 ) ( 6.3 ) ] .",
    "ingredients": [
        {
            "name": "Mecasermin",
            "code": "7GR9I2683O"
        },
        {
            "name": "BENZYL ALCOHOL",
            "code": "LKG8494WBH"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH"
        },
        {
            "name": "SODIUM ACETATE",
            "code": "4550K0SC9B"
        },
        {
            "name": "ACETIC ACID",
            "code": "Q40Q9N063P"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "organization": "Eton Pharmaceuticals, Inc.",
    "name": "Increlex",
    "effectiveTime": "20250507",
    "indications_original": "Severe Primary IGF-1 Deficiency (Primary IGFD)\n                  \n                  INCRELEX is indicated for the treatment of growth failure in pediatric patients 2 years of age and older with:\n                  \n                     severe primary IGF-1 deficiency or\n                     growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.\n                  \n                  Severe Primary IGF-1 deficiency (IGFD) is defined by:\n                  \n                     height standard deviation score ≤ –3.0 and\n                     basal IGF-1 standard deviation score ≤ –3.0 and\n                     normal or elevated growth hormone (GH).",
    "contraindications_original": "INCRELEX should be administered subcutaneously. ( 2.2 ) Injection sites should be rotated to avoid lipohypertrophy. ( 2.2 ) Recommended starting dosage: 0.04 mg/kg to 0.08 mg/kg twice daily. If well-tolerated for at least one week, the dose may be increased by 0.04 mg/kg per dose, to the maximum dose of 0.12 mg/kg given twice daily. ( 2.1 )",
    "adverseReactions_original": "Known Hypersensitivity\n                  \n                  INCRELEX should not be used by patients who are allergic to mecasermin (rhIGF-1) or any of the inactive ingredients in INCRELEX, or who have experienced a severe hypersensitivity to INCRELEX [see Warnings and Precautions (5.2) and Adverse Reactions (6.3)].\n                  \n                  \n                     Closed Epiphyses\n                  \n                  INCRELEX should not be used for growth promotion in patients with closed epiphyses.\n                  \n                     Malignant Neoplasia\n                  \n                  INCRELEX is contraindicated in pediatric patients with malignant neoplasia or a history of malignancy [see Warnings and Precautions (5.7) and Adverse Reactions (6.3)]."
}